Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part ...

Sarclisa was approved by the FDA in 2020 in combination with pomalidomide and dexamethasone for adults with multiple myeloma ...

Poseida Therapeutics’ P-BCMA-ALLO1 receives US FDA RMAT designation to treat relapsed/refractory multiple myeloma: San Diego Tuesday, September 17, 2024, 17:00 Hrs [IST] Poseida ...

The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.

Following promising preliminary findings from a phase 1 study, the FDA granted P-BCMA-ALLO1 regenerative medicine advanced ...

Patti Scialfa, Bruce Springsteen’s Wife and E Street Bandmate, has been diagnosed with multiple myeloma. Find out more on ...